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Abstract
The ideal clinical diagnostic system should deliver rapid, sensitive, specific and reproducible results while minimizing the
requirements for specialized laboratory facilities and skilled technicians. We describe an integrated diagnostic platform, the
‘‘FilmArray’’, which fully automates the detection and identification of multiple organisms from a single sample in about one
hour. An unprocessed biologic/clinical sample is subjected to nucleic acid purification, reverse transcription, a high-order
nested multiplex polymerase chain reaction and amplicon melt curve analysis. Biochemical reactions are enclosed in a
disposable pouch, minimizing the PCR contamination risk. FilmArray has the potential to detect greater than 100 different
nucleic acid targets at one time. These features make the system well-suited for molecular detection of infectious agents.
Validation of the FilmArray technology was achieved through development of a panel of assays capable of identifying 21
common viral and bacterial respiratory pathogens. Initial testing of the system using both cultured organisms and clinical
nasal aspirates obtained from children demonstrated an analytical and clinical sensitivity and specificity comparable to
existing diagnostic platforms. We demonstrate that automated identification of pathogens from their corresponding target
amplicon(s) can be accomplished by analysis of the DNA melting curve of the amplicon.
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Introduction
The ability to rapidly detect and distinguish multiple infectious
organisms is critical for the accurate diagnosis of seasonal and
sporadic outbreaks, emerging pathogens and agents of bioterror-
ism [1,2,3,4]. Accurate pathogen identification allows clinicians to
determine the need for additional ancillary diagnostic testing,
antibacterial or antiviral therapy and can inform decisions
regarding hospitalization and infection control measures [5,6,
7,8,9].
Standard microbiological testing can require several days for
initial identification of a pathogenic organism, and many
organisms cannot be recovered using conventional techniques
[10,11]. Molecular methods, particularly the polymerase chain
reaction (PCR) have expanded the range of pathogens that can be
identified in clinical laboratories. However, existing diagnostic
assays and technologies are either limited in scope or highly
complex [12].
Although it has many advantages, the introduction of PCR
into the standard clinical microbiology and virology laboratory
has been associated with practical challenges [13] that have
limited routine use to large hospital or reference laboratories.
Specialized training and facilities are required for technicians to
perform PCR-based testing. For example, physically separated
locations for sample preparation, formulation of reagents,
reaction set up and amplification are needed to minimize the
potential for contamination which can lead to false positive
results. Even simple PCR platforms have instrument require-
ments that may challenge the capacity of clinical laboratories
[14,15,16,17].
PCR assays for infectious disease range from the relatively
simple, in which a pathogen is identified by the detection of a
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of pathogens [18]. Multiplex PCR allows the potential amplifica-
tion of many nucleic acid targets within a single reaction [19,20,
21,22,23,24,25,26,27,28], and in theory is an ideal method for
multi-pathogen detection. However, multiplex PCR has several
practical limitations. Non-specific products generated through
primer-primer interactions interfere with amplification of the
actual targets and decrease sensitivity. In addition, as more true
targets are amplified, it becomes increasingly difficult to
distinguish the amplification products, although both bead-array
and microchips have been used to accomplish this [29,30,
31,32,33]. These constraints have limited the ability of multiplex
PCR to interrogate a large number of targets, and reports of
more than 8-deep multiplexing are uncommon [34,35,36,37,38,
39,40].
Despite the limitations, multiplex PCR strategies have already
demonstrated clinical utility, particularly for detection and
identification of pathogens causing respiratory tract infection
[17,35,38,39,41,42]. Multiplex PCR is an attractive diagnostic
option for respiratory infections for several reasons. The
differential diagnosis of respiratory infections, such as bronchi-
olitis and pneumonia, includes a large number of potential
pathogens that cause similar signs and symptoms [43,44,45].
Further, conventional diagnostic testing for respiratory pathogens
is limited by poor sensitivity or prolonged turnaround time of
antigen or culture-based testing. Finally the emergence of novel
pathogens that may result in severe disease, such as SARS and
swine-origin influenza A (H1N1-2009), requires the availability of
diagnostic testing with enough flexibility to introduce new targets
rapidly.
Sensitivity of detection is another important consideration when
developing diagnostic tests, as even very low levels of pathogen can
cause disease. Nested PCR is an exquisitely sensitive methodology
in which a target is amplified in a two-step process. In the first
stage, a template is amplified using a pair of ‘‘outer’’ primers. This
PCR product is diluted and subjected to a second stage
amplification using primers located within the first PCR amplicon.
The second stage product can be detected by real-time or end-
product analysis. Nested PCR increases sensitivity over conven-
tional PCR due to the ability to perform up to 50 or 60 total cycles
of PCR. Specificity of nested PCR is similar to that of probe-based
assays, as all 4 primers must match the template [1,46,47,48,
49,50,51]. Although the use of nested primer sets was described
very early in the history of PCR [52] it has not been widely
deployed in clinical settings because, in most systems, it is an open-
tube procedure that is highly subject to self-contamination.
An integrated system that can interrogate a clinical sample
for a broad range of pathogens is highly desirable in both
diagnostic laboratory and clinical settings [12,17,53]. Here we
describe a novel diagnostic platform, the ‘‘FilmArrayH’’, which
combines automated sample preparation, nucleic acid extrac-
tion and PCR-based detection of 31 separate targets from a
single unprocessed sample in one hour. It combines nesting and
multiplexing of the PCR (referred to here as nested multiplex or
‘‘nmPCR’’) together with DNA melting curve analysis [54] to
detect and distinguish multiple pathogens simultaneously.
Because the sample manipulations and reactions are performed
in an enclosed pouch, there is low risk of laboratory
contamination. We detail our validation of the system using
cultured respiratory pathogens and demonstrate its utility using
clinical samples obtained from children with respiratory
infections. The FilmArray and the FilmArray Respiratory
Panel (RP) pouch have since received FDA clearance for use
as an in vitro diagnostic (IVD) device.
Methods
The pouch
Each FilmArray pouch is comprised of an injection molded
polypropylene reservoir (the ‘‘fitment’’, 120 mm long, 10 mm
wide, 25 mm high, ‘‘A’’ in Figure 1B) heat welded to two sheets of
a polyester/polypropylene film containing a copolymer adhesive
layer. The sheets of film are welded together using heated plates to
form the pattern of channels and ‘‘blisters’’ (‘‘C’’ through ‘‘H’’ in
Figure 1B) comprising the sample processing stations and an area
containing a 102-well array for the second stage PCR. The fitment
contains 12 reservoirs (6 mm inner diameter on 9 mm spacing)
that hold the biochemical reagents. During pouch manufacture
three additional reagents are inserted into the appropriate blisters
of the pouch and the film is sealed shut under vacuum. Ceramic
beads are inserted into the sample lysis blister (‘‘C’’ in Figure 1). A
lyophilized pellet of silica-magnetic beads is inserted into blister
‘‘E’’ (Figure 1). A lyophilized pellet of the oligonucleotides (Idaho
Technology, Inc. (ITI)) used in the first stage multiplex PCR is
inserted into blister ‘‘G’’.
The second stage PCR array is manufactured from 0.5 mm
thick black polycarbonate plastic. 102 wells of 1 ml volume each
are drilled into the array (‘‘I’’ of Figure 1B and Figure 2).
Laminating film is heat-sealed to the back of each array and 96
arrays are placed on a platen on the bed of a piezo-electric
microarraying instrument (Nano-Plotter NP2.1e, GeSiM,
Großerkmannsdorf, Germany). The second stage primer sets are
dispensed into the wells of the array using the standard GeSiM
Nano-Tip. After spotting, the arrays are sealed with a second layer
of laminating film containing a matching array of holes (Figure 2)
and then attached to the outside of the pouch (‘‘I’’ in Figure 1)
using pressure sensitive adhesive film.
All of the other biochemical reagents are freeze-dried into the
12 wells of the fitment. Moving from left to right in Figure 1 the
wells contain:
Well 1: Process control material (Schizosaccharomyces pombe cells).
Wells 2, 3, 4, 5: Wash buffer
Well 6: Nucleic acid elution buffer.
Well 7: Reverse transcription/first stage PCR master mix:
Well 8: Dilution buffer
Wells 9, 10: Second stage PCR master mix: containing
LCGreenH Plus+ (ITI),
Well 11: empty
Well 12: Overflow reservoir for the second stage PCR mix.
After these reagents are loaded into pouches a ‘‘plunger tree’’
(‘‘B’’ in Figure 1B) is inserted into the fitment and the pouches are
placed in a Genesis Lyophilizer (VirTis, Gardiner, NY). At the end
of the lyophilization cycle, while the pouches are still under
vacuum, the plunger tree is pushed down into the fitment so as to
preserve the vacuum in each of the wells. To maintain the vacuum
(in the fitment and blisters) during long term storage, pouches are
packaged in a cylindrical aluminum can and sealed under vacuum
inside an aluminized polyester bag. Vacuum storage of the pouch
serves three functions. It helps to maintain the integrity of the
freeze dried reagents during long term storage, it enables sample
and hydration solution to be delivered in an unmetered fashion
and it minimizes the formation of air bubbles in the pouch, which
can be difficult to control or remove from microfluidic systems
[55].
The instrument
The FilmArray instrument is 39.1 cm long625.4 cm
wide616.3 cm high, weighs 8.2 kg (Figure 3) and runs on 120–
220 V AC power. It communicates with PC side software through
Automated Nested Multiplex PCR System
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TM) cables. The instrument contains
two Peltier devices to thermocycle the first and second stage PCR
reactions, a blue LED to illuminate the second stage PCR array
and a digital camera to record fluorescence generated in the
second stage PCR.
The movement of liquid through the pouch is controlled by
three pneumatic elements within the instrument. Pistons (located
behind ‘‘B’’ in Figure 1) depress the plungers in the top of the
fitment and thus inject reagents from the fitment into the pouch.
Silicone bladders inflate over the pouch blisters to move liquid
between blisters. Blunt edged pistons (‘‘Hard seals’’), positioned
over the channels connecting the blisters control liquid movement
between the blisters. Electronically controlled valves activate the
pistons, bladders and hard seals in a coordinated pattern to
regulate the flow of liquid through the pouch.
Nested PCR assay design
Organism related sequence information (complete genomes,
gene sequences and partial gene sequences) was obtained from
NCBI (http://www.ncbi.nlm.nih.gov). Regions containing large
conserved segments of protein sequence or conserved 59 UTR
sequences (for human Rhinovirus (HRV) and Bordetella pertussis (B.
per)) were selected for assay targets (Table 1). Nearest neighbor
information was obtained through the NCBI Taxonomy database
Figure 1. FilmArray pouch. (A) A FilmArray pouch was injected with
mock sample (here colored blue for illustrative purposes) in the left side
injection port and hydration solution (colored red) in the right side
injection port. (B) The blisters of a FilmArray pouch were filled with
different coloring (and the channels between the blisters heat sealed
shut). In this pouch the plunger tree was made from plastic dyed blue.
The fitment and film are normally at right angles to each other; for
clarity the pouch has been flattened. (C) A schematic of the pouch
showing a trace of the blisters, channels and array wells (black) and the
functional areas of the pouch (red).
doi:10.1371/journal.pone.0026047.g001
Figure 2. Schematic of second stage PCR mix entering the
array. The layers of film and adhesive attaching the array to the pouch
are separated to show the flow of liquid into the cells of the array
(figure is not to scale). From the top the layers are: 2
nd pouch film, 1st
pouch film, array adhesive layer (orange), pricked cover film, array
(black, with wells), and array cover film. All of the actual layers are
transparent except for the array itself. Second stage PCR primers are
spotted into the cells during manufacture and air-dried (Methods).
Arrows show the flow of PCR master mix (without primers) entering the
array through a hole cut in the 1
st pouch film.
doi:10.1371/journal.pone.0026047.g002
Figure 3. FilmArray instrument with pouch being loaded.
doi:10.1371/journal.pone.0026047.g003
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alignments to ensure specificity of assay design. Assays were
designed with a first stage PCR amplicon length of 145 to 450
(median 193) base pairs (bp). Primer sites for the second stage PCR
amplicons were located within the first stage PCR amplicon and
were designed to generate an amplicon of approximately 49 to 180
(median 88) bp. Primer lengths were between 17 and 37 bp and
the annealing temperatures ranged from 54uCt o7 2 uC. Degen-
eracy of up to 64-fold was used in some primer designs in order to
accommodate sequence diversity but degenerate bases were not
allowed within 4 bases of the 39 end. In order to avoid higher
order degenerate primers, some assays utilize multiple indepen-
dent primers. When multiple primers were needed to achieve full
coverage of diverse organisms, they were either separated as pairs
in distinct wells of the array, or combined as a multiplex in single
wells.
1
st and 2
nd stage assays were initially tested separately to ensure
that they produced the expected amplification product, and that
RNA assays were dependent on the presence of reverse-
transcriptase in the reaction mix. An additional criterion was that
all 1
st and 2
nd stage primers must function well at the same
annealing temperature. First and 2
nd stage assays were then
combined to form a singleplex, nested assay and tested for
efficiency, sensitivity and specificity using quantification cycles (Cq,
[58]) as the readout. The first stage primers from nested assays
with good overall amplification efficiency were subsequently
combined as a multiplex. The Cqs for each assay performed
either as a singleplex or multiplex in the first stage were then
compared. For most assays the Cqs were quite similar. For the few
cases where this was not true, moving one or the other primer a
few nucleotides along the target sequence was sufficient to rescue
the performance in the first stage multiplex PCR. After each
redesign all assays were retested as described.
Performing a FilmArray run
Pouch preparation. The freeze-dried reagents in the
fitment are resuspended with hydration solution using a 3 ml
syringe fitted with a blunt metal cannula. The cannula is inserted
into the hydration port (‘‘X’’ in Figure 1B) where it breaks a
septum in the port. The vacuum in the fitment draws liquid to fill
wells 2 through 11 (,80 ml each). Sample to be tested (a
nasopharyngeal aspirate (NPA) in PBS or a nasopharyngeal swab
(NPS) in viral transport medium) is mixed with two volumes of a
denaturing sample buffer and injected into the pouch through the
sample injection port (‘‘Y’’ in Figure 1B). Well 1 draws in 300 ml
of this mixture). The loaded pouch is then inserted into the
FilmArray instrument, and the pouch and sample are identified
to the instrument by the operator using a hand-held bar code
reader. After the run is started all further steps are performed by
the instrument.
Table 1. FilmArray RP Pouch Pathogens, Gene Targets and LOD95.
Organism Gene Target(s) Strain
a LOD95
b
AV Hexon Type 1 300
BoV NP-1 Clinical Sample 4000
B. per Toxin A639 4,000
C. pne ompA TW183 3000
CoV 229E Polymerase VR-740 4
CoV HKU1 Nucleoprotein PCMC 6123 1.9610
6
CoV OC43 Nucleoprotein VR-759 600
CoV NL63 Nucleoprotein NR-470 5
EV 59 UTR Echovirus 6 30,000
c
hMPV Nucleoprotein hMPV-16/IA10-2003 Type A1 2
HRV 59UTR 1A 1
Flu A (H1N1) Matrix
d,N S 1
d, HA1 A/Brisbane/59/07 200
Flu A (H1N1- 2009) Matrix
d,N S 1
d, HA1-2009 A/SwineNY/03/2009 100
Flu A (H3N2) Matrix
d,N S 1
d, HA3 A/Wisconsin/67/2005 5
Flu B Hemagglutinin B/FL/04/06 60
M. pne Toxin M129 – Type 1 30
PIV 1 Hemagglutinin Type 1 500
PIV 2 Fusion Type 2 10
PIV 3 Fusion Type 3 10
PIV 4 Fusion Type 4a 5,000
RSV Matrix RSV Type A 2
aSee Table S1 for the source of the organisms.
bLoD concentrations are expressed in CFU/ml and TCID50/mL for bacteria and viruses respectively except for C. pne and BoV (DNA copies/mL) and CoV-HKU1 (RNA
copies/ml) respectively (Methods).
cThe LoD for Enterovirus (30,000 TCID50/ml) is based on positive results for the Entero1 or Entero2 assays. A final result of Human Rhinovirus/Enterovirus based on the
combination of 6 different assays (HRV1–4, Entero1 and Entero2) can be obtained at much lower concentrations (,300 TCID50/mL).
dThe Flu A Matrix and NS1 gene assays are referred to as ‘‘pan1’’ and ‘‘pan2’’ respectively in the text.
AV, Adenovirus; B. per, Bordetella pertussis; BoV, Bocavirus; C. pne, Chlamydophila pneumoniae; CoV, Coronavirus; EV, Enterovirus; FluA, Influenza A ; FluB, Influenza B;
hMPV, Human metapneumovirus ; HRV, human Rhinovirus; M. pne, Mycoplasma pneumoniae; PIV1–4, Parainfluenza viruses 1–4; RSV, Respiratory Syncytial Virus.
doi:10.1371/journal.pone.0026047.t001
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cabinet following the appropriate biohazard guidelines for working
with potentially infectious samples. For the RP pouch, the
FilmArray instrument may be operated on a laboratory bench
or inside a biosafety hood.
Sample lysis. Well 1 of the fitment contains the sample
together with S. pombe yeast cells freeze-dried into the well as a
processing control. A piston adjacent to the fitment forces the
contents of well 1 into the large cell lysis blister (‘‘C’’ of Figure 1)
where viruses and bacteria (as well as the yeast control material
freeze dried into well 1) are mechanically disrupted by 60 seconds
of vigorous agitation with ceramic beads. The force for this
disruption comes from a rotating metal bar located behind the
plane of the pouch shown in Figure 1.
Nucleic acid purification. Total nucleic acid in the sample
is isolated by moving the sample lysate across the silica-magnetic
beads particles present in well ‘‘E’’. A retractable permanent
magnet (located behind blister ‘‘E’’ in Figure 1) is used to collect
the magnetic beads in this blister. Magnetic beads are
concentrated in blister ‘‘E’’ with the magnet and washed 3 times
with buffer from wells 3, 4 and 5. After the nucleic acid binding
step, blister ‘‘C’’ serves as a waste container for later steps in the
process. Nucleic acid is eluted with buffer brought in from well 6
and all of the eluted material is moved through blister ‘‘F’’ into
blister ‘‘G’’ where the mixture serves to resuspend the freeze dried
pellet of first stage PCR primers.
cDNA synthesis and outer multiplex PCR. Reverse
transcription and first stage PCR occur in blisters ‘‘F’’ and ‘‘G’’.
PCR master mix (containing the reverse transcriptase) from well 7
of the fitment is pushed into blister ‘‘F’’. Bladders push both
blisters against a Peltier device behind the pouch. A mechanical
hot start is achieved by holding the contents of the two blisters
separate (using a hard seal between them) until they reach 54uC.
Reverse transcription occurs during an initial 3 minute hold at
54uC. The first stage PCR consists of 26 cycles of 94uC for
4 seconds followed by 60uC for 19 seconds. During reverse
transcription and PCR cycling the contents of the reaction are
mixed by moving the liquid between blisters ‘‘F’’ and ‘‘G’’. At the
end of cycling the reaction is diluted approximately 225-fold into
second stage PCR master mix by two successive dilution steps, first
with TE buffer from well 8 and then with PCR master mix from
wells 9 and 10.
Nested PCR. The second stage PCR occurs in the wells of
the array (‘‘I’’ in Figure 1). A mechanical hot start is achieved by
holding the second stage PCR master mix/diluted template
mixture at 90uC while the array is heated to 75uC. The array is
then flooded with this mixture (shown schematically in Figure 2)
which hydrates the inner primers in their individual wells. To seal
the PCR wells shut, a clear plastic bladder in the instrument is
inflated over the array after it is flooded. Second stage PCR
cycling conditions are 94uC for 4 seconds and 63uC for 19 seconds
for 30 cycles. Ramp rates are approximately 1.7uC/sec. Images
can be acquired once per PCR cycle in order to generate
conventional real-time PCR amplification curves.
Amplicon melt analysis. After the final PCR cycle the
sample is held at 63uC for 5 sec followed by a linear ramp in
temperature from 68uCt o9 5 uC at a nominal rate of 0.5uC/
second. Images are acquired 10 times per second.
FilmArray data analysis
The FilmArray instrument is capable of collecting fluorescence
images and corresponding temperature data during the temper-
ature ramp performed after the second stage PCR. The melt
curve, defined as the average fluorescence intensity of each well as
a function of temperature, is the basis for the automated organism
detection algorithm described below. During the development of
the system, the instrument was also programmed to acquire
images once per PCR cycle in order to generate conventional real-
time PCR amplification curves and corresponding Cq values.
However the amplification data are not used in the automated
organism calls for the commercial FilmArray system (see Results).
For the automated analysis, a hierarchy of calls is made: first for
individual wells, then for individual assays (when specific primers
are replicated in multiple wells of the array) and finally for each
organism. This analysis is first performed on the control assays. If
the controls return positive results, the analysis proceeds to the
pathogen assays and the results are reported. If controls assays
return a negative result, the run is declared ‘Invalid’ and no
organism results are reported.
For each well, curve shape and peak location analyses of the
melt curve are used to make a ‘‘Positive’’ (amplicon present) or
‘‘Negative’’ call. If two or more replicate wells are Negative for any
one assay, then assay is called ‘‘Negative’’. Next, if two of the
melting temperatures (Tms) for positive replicates are within assay-
specific limits (see Results) then the software assigns a positive call
to the assay. For organisms with a single associated assay the final
test result of ‘Detected’ or ‘Not Detected’ is based on the assay call.
For influenza A and Rhinovirus/Enterovirus, the final test result is
based on the integration of all associated assays.
Sources of viruses, bacteria and clinical samples
Viruses and bacteria used in this study are indicated in Table
S1. Growth, quantification and verification of viral and bacterial
cultures were performed by Zeptometrix (Buffalo, NY). Bocavirus
(BoV) and Coronavirus (CoV) HKU1 could not be grown in
culture. Instead, well-characterized clinical specimens were
utilized and quantified in copies per ml by real-time PCR against
a standard curve of synthetic template.
Residual clinical NPA specimens (stored frozen at 280uC) came
from children younger than 18 years who had NPA collected for
respiratory viral testing by direct fluorescent antibody (DFA) and
culture at Primary Children’s Medical Center (PCMC), Salt Lake
City, UT between 2006 and 2008. Approximately half of the NPA
specimens chosen for analysis were negative by DFA and viral
culture. FilmArray testing was performed at both PCMC and ITI.
PCR results were not used to inform clinical management or
reported to microbiology technicians performing DFA and viral
culture.
FilmArray data used for tuning the melt calling algorithm were
acquired at sites performing beta testing of the instrument. The
data used to validate the algorithm were acquired during clinical
trials of the FilmArray system and RP pouch at the Medical
University of South Carolina (Frederick S. Nolte, PhD), Detroit
Medical Center (Hossein Salimnia, PhD), and Children’s Medical
Center of Dallas (Beverly Rogers, M.D.).
The institutional review boards of the University of Utah and
PCMC approved this study and granted a waiver of informed
consent because the patient samples were de-identified. All
external clinical studies were performed with appropriate IRB
approval. Data from these sites were de-identified before being
sent to Idaho Technology.
Direct Fluorescent Antibody testing and viral culture
The PCMC microbiology laboratory performs DFA for seven
respiratory viruses: Influenza A (FluA), Influenza B (FluB),
Respiratory Syncytial Virus (RSV), Parainfluenza viruses 1–3
(PIV 1–3) and Adenovirus (AV) using a panel of DFA assays
(Simulfluor respiratory screen, Light Diagnostics, Temecula, CA)
Automated Nested Multiplex PCR System
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detected with a specific hMPV monoclonal antibody (Diagnostic
Hybrids, Athens, OH).
Viral cultures are performed using a single cell line (R-Mix-Too;
Diagnostic Hybrids) with an exit stain at 72 hours. The sensitivity
of DFA testing, compared with viral culture, was 90% for FluA,
72% for FluB, 99% for RSV, 77% for PIVs, and 92% for hMPV,
with specificity of 90% for all of the viruses in the PCMC
laboratory [59,60]. Technicians at ITI and PCMC were blinded
to DFA results while evaluating NPA samples using FilmArray.
Reproducibility was not evaluated in this study.
Statistical analysis of the FilmArray versus DFA results
McNemar’s test is used to compare the DFA results to the
FilmArray results [61]. The test compares the number of
discordant results, shown in the off diagonals of the paired
262 table (Table 2), to estimate the probability that the two
methods have equal sensitivity and specificity. We chose to use
the terms positive % agreement and negative % agreement to
report the test characteristics of the FilmArray respiratory panel.
Positive percent agreement (sensitivity) is the percent of time that
FilmArray RP detected a virus when DFA detected it. Similarly,
negative percent agreement (specificity) is the percent of time
that FilmArray RP did not detect a virus when DFA did not
detect it.
If the sensitivity and specificity of the two methods are equal, the
two off diagonals should be approximately equal and the estimated
probability of being the same should be high. If one method is
more sensitive or specific than the other, one of the off diagonal
cell counts would be larger than the other and the estimated
probability that the two methods have the same sensitivity and
specificity would be low. The test does not provide the user with
the information to determine that one method is more sensitive or
the other is more specific, rather only gives them the power to say
that they are different.
Results
Optimization of the FilmArray chemistry
Initial development of the system was performed using DNA
and RNA targets from Saccharomyces cerevisiae and Schizosaccharomyces
pombe. To optimize the amplification of RNA targets we used
intron-spanning primers to detect mRNAs and to exclude genomic
DNA. Nested assays developed on conventional PCR instruments
were moved into the FilmArray platform. Whole organisms or
purified nucleic acid were tested in different steps of the pouch to
evaluate both the nucleic acid purification and nmPCR portions of
the process.
To maximize the sensitivity of the system, we determined the
number of cycles in the first stage PCR that are needed to enter
the plateau phase of the reaction [62,63]. For the first 25 cycles of
the 1
st stage multiplex reaction, amplification of specific product is
efficient, and each additional 1
st stage cycle reduces the Cq in the
nested reaction by one. After this point there is diminished
efficiency of the first stage PCR and for this reason, the first stage
PCR is run for 26 cycles.
The completed first stage PCR mixture is diluted and then
mixed into fresh PCR reagents. We determined empirically that
two successive dilutions of ,15 fold were necessary and sufficient
to minimize primer carryover from the first stage PCR. Dilution of
less than 100 fold generated nonspecific amplification products in
the second stage PCR. Dilution of more than 300 fold caused a
reduction in sensitivity.
The second stage PCRs are performed in individual wells of a
high-density polycarbonate array (‘‘I’’ in Figure 1 and shown
schematically in Figure 2). The format of the array is analogous to
Table 2. Comparison of FilmArray RP to DFA.
FilmArray RP DFA
Positive Percent
Agreement
Negative Percent
Agreement
Discordance
P Value
c
Pos
a Neg
a (95% CI)
b (95% CI)
b
AV Pos 22 32 84.6 (65.1–95.6) 89.4 (85.4–92.6) ,0.001
Neg 4 270
hMPV Pos 4 10 66.7 (22.3–95.7) 96.9 (94.4–98.5) 0.021
Neg 2 312
Flu A Pos 14 2 100 (76.8–100) 99.4 (97.7–99.9) 0.50
Neg 0 312
Flu B Pos 1 8 100 (2.5–100) 97.6 (95.2–98.9) 0.008
Neg 0 319
PIV1 Pos 6 0 54.5 (23.4–83.3) 100 (98.8–100) 0.063
Neg 5 317
PIV2 Pos 10 8 90.9 (58.7–99.8) 97.5 (95.1–98.9) 0.039
Neg 1 309
PIV3 Pos 19 28 95.0 (75.1–99.9) 90.9 (87.1–93.9) ,0.001
Neg 1 280
RSV Pos 37 9 94.9 (82.7–99.4) 96.9 (94.2–98.6) 0.035
Neg 2 280
aPositive or Negative test result comparing FilmArray RP (new test) to DFA (reference standard subject to error). (N=328)
bClopper-Pearson 95% confidence Interval.
cMcNemar test, comparing discordant cells (FilmArray positive, DFA negative) vs (FilmArray negative, DFA positive).
doi:10.1371/journal.pone.0026047.t002
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separated for identification. In contrast to a standard microarray,
PCR amplification is performed in each well. Specific primers that
nest within a particular first stage PCR amplicon are dried into
each well; each assay is present in triplicate within the array. The
double-stranded DNA binding dye LCGreenH Plus [54,64] is used
to monitor fluorescence changes during PCR amplification and
during a post-PCR amplicon melt.
The FilmArray pouch incorporates three controls to assess the
performance of key steps in the system. As an RNA process
control, the yeast S. pombe is freeze dried into the first well of the
fitment. Outer and inner primers targeting a spliced mRNA from
S. pombe are included in the pouch. A positive result for this assay
provides evidence that all steps of the pouch completed correctly.
A double stranded DNA oligonucleotide in the first stage PCR
master mix and the appropriate nested assay monitors all steps
from the first stage PCR forward. A different DNA oligonucleotide
is spotted into the array along with the appropriate forward and
reverse primers to monitor the second stage PCR.
Development of respiratory pathogen assays for the
FilmArray
In parallel with the development of the FilmArray instrument
and pouch we designed a panel of assays to detect viruses and
bacteria known or suspected to cause upper respiratory tract
infection in humans. Pathogens were chosen in consultation with
pediatric infectious disease experts (AJB, CLB). Primers were
designed to amplify conserved regions of the targets using standard
software and alignment tools. The assays were initially optimized
in conventional PCR instruments, using as template either
organism from reference collections or pediatric NPA samples
that tested positive for respiratory viruses by conventional (DFA)
testing or the assays described here. Sequencing was used to
confirm target identity. A successful set of assays for 23 targets
from 21 pathogens was transferred to the pouch. The final
FilmArray RP pouch contains 61 primers in the outer multiplex (of
which four are for controls) and 31 inner second stage PCR assays
(spotted in triplicate on the array with nine empty wells as negative
controls). Pathogens and gene targets in the optimized RP pouch
are listed in Table 1. The yeast RNA process control and the
second stage PCR control are used to catch failures in the different
steps of the pouch.
Detection of virus and bacteria using the FilmArray
instrument and pouch
Typical amplification and melt curves generated using a
research version of the FilmArray instrument and RP pouch are
shown in Figure 4. FluA H1 virus (200 Tissue Culture Infectious
Doses-50% (TCID50)) injected into an RP pouch produced
amplification products in the wells of the array containing PCR
primers specific for all of the FluA H1 specific targets (Figure 4A).
Melting curves generated from wells for a given assay have Tms
that are characteristic of the amplicons from those targets
(Figure 4B). The FluA H3 assay, which should not be positive
for this virus, does not show evidence of amplification or melt
peaks. Figure 4E and F show the result of injecting a very high
level of another organism, B. per, into a FilmArray pouch. The
amplification curves for the B. per assay replicates have a Cq of 5.
This is the earliest Cq observed in the system and represents
dilution and second stage amplification of an outer amplicon that
has fully entered plateau in the first stage reaction.
FilmArray can detect multiple targets in a single assay, and in
particular, detect a low-copy target in the presence of a different,
high-copy target. Figure 4C and D shows the results from a pouch
in which both the high-titer B. per and low-titer FluA were injected.
The B. per is detected early (low Cq), as expected. In addition, all of
the Flu A target amplicons are detected, with similar Cqs and Tms
as found for the FluA sample alone.
Figure 4E and 4F also show the RNA process control and the
second stage PCR control. The assays amplify and produce the
expected characteristic melts indicating that 1) all of the different
steps of the pouch performed as expected and 2) the sample did
not inhibit the pouch chemistry.
Pre-clinical evaluation of the FilmArray with pediatric
NPA samples
To determine whether the FilmArray system would detect
organisms in patient samples, we performed a study using
pediatric NPA samples previously tested for respiratory infection
at PCMC by DFA. Pre-clinical testing was performed at ITI and
also during a 2-month placement of an instrument within the
PCMC microbiology laboratory. Positive organism calls were
made by expert users examining the amplification and melt curves.
Three hundred and twenty eight samples were tested by both DFA
and FilmArray. The results were compared for those viruses
identified by both testing methods. When analyzed separately,
similar results were obtained from both the research and clinical
laboratories (data not shown) and thus combined data is presented.
The FilmArray, with 21 respiratory pathogen assays, identified
significantly more pathogens than DFA in these pediatric samples
(Figure 5). FilmArray testing decreased the number of clinical
samples with no pathogen identified from 63% by DFA to 19% by
FilmArray (p value,0.0001). For the pathogens tested by DFA,
the concordance between FilmArray and DFA testing was high.
Positive percent agreement with DFA ranged from 55%–100%,
although for most the agreement was .90% (Table 2). The two
pathogens with the lowest percent agreement were PIV1 (55%)
and hMPV (67%). Some samples that were PIV1 positive by DFA
were PIV3 positive by FilmArray and were confirmed to be PIV3
by sequence analysis. Because the FilmArray testing was done
retrospectively, DFA could not be repeated. For hMPV, there
were too few positive samples to fully interpret discordant results.
Using amplicon melting to automate analysis of the
assay results
A diagnostic system that automates the technically demanding
steps of nucleic acid isolation and PCR amplification would benefit
from automated analysis of the PCR results. FilmArray runs
generate large amounts of data in the form of real time
amplification curves and the associated melt curves. In similar
systems the properties of the amplification curve are used to make
a positive or negative call for that assay [65]. In the course of
analyzing the FilmArray data from reference strains and clinical
samples, we observed that the amplicon melt curve shapes and
Tms were highly specific to the organism targeted by the nested
PCR and thus could provide an additional filter for detecting each
organism. For high or moderate titer organisms, the FilmArray
system produces both robust amplification and melt curves with a
high signal-to-noise ratio (Figure 4A and B). For very low titer
organisms, the amplification curve is often obscured by the noise
inherent in thermocycling. For example, Figure 6 shows the
amplification and melt curve data from a pouch injected with a
very low level FluA sample (1/200
th of that in Figure 4). Of the
three assays in the pouch that can detect this organism, neither the
FluA pan2 nor the FluA H1 pan amplification curves show a rise
above baseline; only the FluA pan1 assay produced significant
Automated Nested Multiplex PCR System
PLoS ONE | www.plosone.org 7 October 2011 | Volume 6 | Issue 10 | e26047Figure 4. Real-time amplification and melt curves from the array. Respiratory Pathogen pouches were injected with viral transport medium
spiked with 200 TCID50 FluA H1-seasonal (panels Aand B), 4610
6 cfu B. per and 200 TCID50 FluA-H1 (panels Cand D), or 4610
6 cfu B. per (panels Eand F)a n d
r u no nt h eF i l m A r r a yi n s t r u m e n t .R e a ltime amplification curves (panels Aand Cand E) and post-amplification melt curves (panels B and Dand F)f o rs e l e c t e d
wells on the array are shown. Assays are spotted in triplicate: FluA-pan1 (orange), FluA-pan2 (pink), FluA-H1-pan (red), FluA-H3 (black), B. per (Green), Yeast RNA
process control (dark blue), Second stage PCR control (light blue). For clarity the controls are shown in panels E and F only.
doi:10.1371/journal.pone.0026047.g004
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melt curves for the same sample (Figure 6B). The automated
analysis of the melt curves produced a positive result for the FluA
pan1 and pan2 assays (2 or more of the 3 replicates were positive)
and a negative result for the FluA H1 pan assay (only one melt
curve was positive).
To compare the sensitivity of a detection algorithm based on
melt curve analysis to one based on amplification curves, we had
expert users annotate a total of 18,156 amplification and melting
curves as positive or negative. Automated analysis of the data using
both the amplification and melt profiles produced a sensitivity of
94.7%, a specificity of 99.95%, and an error rate of 4.15%
compared to the expert user’s annotations. By comparison,
analysis of the melt curves alone produced a sensitivity of
97.49%, a specificity of 99.6%, and a total error rate of 2.92%
compared to the expert calls. The higher error rate of the
combined analysis is explained by false negative calls for weak
amplification curves. Therefore we proceeded to develop an
automated analysis of the FilmArray data using only the melt
curves.
To maximize the specificity of melt curve analysis, we
determined the range of possible Tms for amplicons from each
different organism assay. The theoretical melting temperature of a
DNA sequence on the FilmArray instrument was calculated using
the model (modified from [66]):
Tm~T0zTGC   GC{TL=L, ð1Þ
where GC is the mole fraction of G and C bp in the sequence, L is
the length of the amplicon, and To, TGC, and TL are empirically fit
parameters estimated using FilmArray data from samples of
known sequence. GenBank was searched for sequence variants of
each organism and these data were trimmed to the inner PCR
product of the nmPCR. Predicted Tms for these variants were
calculated using the mathematical model determined above (the
data for hMPV are shown in Figure 7A). This distribution of Tms
was used to establish the expected melt range for each assay. These
ranges were expanded beyond the minimum and maximum
predicted Tms to account for system variability (determined by the
Tms of the control assays) and the Tms obtained from initial
clinical testing (Figure 7B). To validate these predictions, the
distributions of Tm data from testing of reference strains
(Figure 7C) and from further clinical evaluations (Figure 7D) were
compared to the initial melt range. The overlap in distribution of
Tms between the different sample sets suggested that the melt
ranges adequately, capture the full diversity of amplicon Tms for
this organism. Narrowing the melt window in this way eliminates
some false positives due to nonspecific amplification (data not
shown).
To maximize sensitivity and specificity of the melting curve
detection algorithm we optimized it using a large training dataset
comprising 1566 RP pouch runs performed both at Idaho
Technology (900 runs) and at external sites (666 runs) (Methods).
The majority of the data generated at Idaho Technology was
derived from contrived samples spiked with dilution series of the
various target organisms (Table S1). Data from external sites was
primarily composed of residual archived clinical samples evaluated
during beta testing of the system. Using a semi-automated process,
Figure 5. Detection rates of the FilmArray RP pouch compared to DFA. Pediatric NPA samples (N=328) were tested either by DFA at PCMC
(yellow bars) or on the FilmArray (Blue bars). The percent of samples in which no virus (Negative) or one of the indicated viruses was detected is
shown. The viruses are grouped into those in which both DFA and FilmArray assays are available or only the FilmArray assay is available.
doi:10.1371/journal.pone.0026047.g005
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specificity are greater than 99% (Table 3, Training Set). To
validate the performance of the detection algorithm, a second
independent dataset consisting of 511 FilmArray runs of clinical
samples was annotated by expert users. As shown in Table 3
(Validation Set), the detection algorithm is able to differentiate
positive and negative melt curves with a high degree of accuracy
(.99.5%).
Using the same training and validation data set, the FilmArray
automated analysis was compared to expert calls for the assay
results (Table 4). Data from the triplicate wells of each assay were
combined to produce a ‘‘Positive’’ or ‘‘Negative’’ assay call. In this
case the results of the automated analysis of the FilmArray RP
system resulted in sensitivity and specificity .99.6%.
Determination of the analytical Limit of Detection for the
FilmArray RP system
To determine at what level the PCR assays in the FilmArray
system could correctly and consistently identify organisms, titered
viral and bacterial respiratory pathogens were spiked into negative
NPS sample matrix collected from healthy individuals or into a
simulated NPS matrix consisting of viral transport medium (VTM)
and a human epithelial cell line. Serial dilutions of the viruses and
bacteria were spiked into NPS samples, both singly and in
combinations of up to 5 organisms per sample. The spiked NPS
samples were then tested on the FilmArray instrument. Quanti-
fication by TCID50 is a measure based on infectivity or
cytotoxicity rather than number of organisms or copies of nucleic
acid. LoD determined in TCID50/mL may not be an accurate
indicator of the relative sensitivity of detection between different
organisms.
An initial estimate of the system Limit of Detection (LoD95,o r
the concentration of organism that can be reliably detected in 95%
or more of the samples tested) was based on the serial dilutions.
Additional samples were then prepared and tested at the estimated
LoD concentration and 10-fold lower to confirm that the correct
organism was detected in at least 95% of the samples at LoD and
in less than 95% of the samples containing 10-fold less organism. A
positive organism detection was determined according to the
automated analysis performed by the FilmArray software. For
multi-assay organism calls such as FluA subtypes, all relevant
assays were required to be positive at the LoD95 level. Column C
in Table 1 shows the FilmArray LoD95 for each pathogen.
The sensitivity of detection was comparable between samples
containing a single organism and those containing up to five
different organisms. Subsequent clinical evaluations determined
that the sensitivity of each assay was appropriate for accurate
detection of clinically relevant pathogen levels in NPS specimens.
It is worth noting in this regard that the LoD concentration for
Coronavirus HKU1 (1.9610
6 RNA copies/mL) is below the
published viral load detected in acute Coronavairus HKU1
infection (8.5–9.6610
6 RNA copies/ml during the first week of the
illness [67]). A full description of the clinical evaluation of the
FilmArray RP pouch for testing NPS samples, performed using the
automated calling algorithm described above, will be published
elsewhere.
Discussion
In the last decade advances in diagnostic testing have led to
changes in clinical laboratory evaluation that have translated
into improved clinical care [60,68,69,70,71,72,73,74]. Despite
these advances, limitations remain in the arena of rapid testing
for multiple pathogens and the ability to move molecular testing
into clinical laboratories, particularly those unable to perform
high-complexity testing. The FilmArray system addresses these
concerns in that it has the capability for high-order multiplex
testing, yet is simple to use and requires minimal hands-on time.
Here we have demonstrated that the system can accurately
detect and identify both DNA and RNA targets from whole
organisms, including those contained within clinical respiratory
specimens. The FilmArray can also effectively detect multiple
targets in a single sample. We have developed and tested the
performance of a clinically relevant panel of respiratory
pathogens, including both viruses and bacteria, and shown
good performance of the system when compared to standard
laboratory methods.
Figure 6. Amplification and melt curves at low target levels. Respiratory Pathogen pouches were injected with viral transport medium spiked
with 1 TCID50 of the FluA- H1 seasonal virus used in Figure 4, and run on the FilmArray instrument. Real-time amplification curves (A) and post-
amplification melt curves (B) for selected wells on the array are shown. Assays are spotted in triplicate: FluA-pan1 (orange), FluA-pan2 (pink), FluA-H1-
pan (red). The ordinate scales are the same as in Figure 4.
doi:10.1371/journal.pone.0026047.g006
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pouch’’ format
The FilmArray is a realization of a ‘‘Lab-on-a-Chip’’ or mTAS
system (micro total analysis system, [75,76]). It implements the
highly sensitive and specific technique of nested multiplex PCR in
an enclosed disposable, the FilmArray pouch. This enables the
considerable benefits of this form of PCR to be realized in settings
where even moderate contamination risk of pathogen or of
amplicon is unacceptable. Ultimately, this ‘‘Lab-on-a-Chip’’-type
format could allow complex molecular methods to be adopted in
‘‘point-of-care’’ settings or field situations, where the patient
presents initially to the healthcare provider [17,77,78,79].
Although the FilmArray pouch manipulates relatively large
volumes of liquid for a mTAS system, it shares several advantages
with such systems. The steps of the system are automated which
reduces operator work-load and error. The process is rapid: the
time lag between one step of the chemistry and the next is
Figure 7. Tm data used to establish assay specific melt windows. Histograms of the theoretical or observed Tms of the hMPV assay are shown.
Tm data for the FilmArray runs includes each of the three replicates of the second stage PCR. A: Tms calculated from 13 sequence variants published
in the NCBI databases. B: Tm data generated during the system beta-testing with 37 banked hMPV-positive patient samples. C: Tm data generated
during the inclusivity testing with 10 hMPV strains representing subtypes A1, A2, B1 and B2. Multiple FilmArray runs of these strains are included in
this data set. D: Tm data from 74 hMPV-positive patient samples collected during the clinical evaluation.
doi:10.1371/journal.pone.0026047.g007
Table 3. Performance of the FilmArray RP melt curve
detection algorithm compared to expert interpretation.
Expert Interpretation Melt Detector Call
Percent
agreement
(95% CI)
Positive Negative
Training Set Positive 37,614 231 99.39 Pos
(99.31–99.47)
Negative 141 108,529 99.87 Neg
(99.85–99.89)
Validation Set Positive 8,153 30 99.63 Pos
(99.48–99.75)
Negative 17 39,323 99.96 Neg
(99.93–99.97)
doi:10.1371/journal.pone.0026047.t003
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the fitment and the blisters also enables a hot start for both the first
and second stage PCRs (see Methods). This eliminates the expense
and inefficiency associated with using chemical or biochemical
means of inhibiting Taq. A physical hot start also has the
additional, unique, advantage that the reverse transcriptase is
prevented from interacting with primers below the desired
temperature of the reaction. This minimizes the formation of
primer dimers or other nonspecific products in the deep multiplex
of the first stage PCR.
The FilmArray lab-in-a-pouch is also an efficient solution to the
‘‘sample to assay’’ problem that many microfluidics systems must
solve [80,81,82]. Typically, for low abundance pathogens,
sensitivity comes from testing a large input sample volume.
However, for multiplex testing, sample will often be limiting and to
keep reagents costs down, the many individual tests must be done
in small volumes. The FilmArray first stage multiplex PCR uses all
of the nucleic acid recovered from the input material (100 mlo f
patient sample). The second stage amplification then allows
specific detection of the analytes in individual 1 ml PCRs without
the loss of sensitivity common in small volume PCRs.
In addition to its increased sensitivity and specificity, nested
PCR simplifies the development of complex multiplex PCR
panels. In order to detect viruses with great sequence diversity (e.g.
AV and HRV) the first stage PCR contains moderately degenerate
primers, or multiple primer sets. Unlike the common observation
with single-stage multiplex PCR reactions [83,84], we observed no
loss of assay sensitivity when comparing nested PCR with the full
complement of primers in the first stage versus a single set of
primers in the first stage (data not shown). For every primer set
that did show a loss of sensitivity, a redesign of the first stage assay
was enough to restore sensitivity without perturbing other assays.
Whiley et al [85] have argued that multiple independent nucleic
acid tests are required to ensure adequate sensitivity for detecting
organisms that have significant sequence variation. Nesting of the
PCRs allows a high level of multiplex in the first stage PCR, which
addresses this concern. We have tested FilmArray multiplex
designs that include 40 different assays and see no loss of sensitivity
compared to single assay formats (M. Rogatcheva, unpublished
data). In the FilmArray RP pouch described here, there are two
pan-influenza A assays (pan1 and pan2 for the MA and NS2 genes
respectively). This increases the likelihood that a novel pandemic
influenza will be detected by the system (as a ‘‘non-subtypeable’’
FluA) because there is a high probability that either one or the
other pan assay will be reactive.
nmPCR is also highly resistant to target competition (Figure 4).
An organism present at very high concentration (10,0006LoD95,
calculated from the data in Table 1) does not inhibit the detection
of a second organism present at low concentration (106LoD95).
This occurs because the first stage PCR is not the direct readout
for the presence of each analyte. Instead it gives the lower
concentration organism adequate amplification boost, (i.e. enrich-
ment) for detection in the second stage PCR.
Detecting organism based on amplicon melts
The automated analysis of FilmArray data is robust to sequence
variation in the target amplicon as well as potential instrument and
pouch variation. The combination of melt detection in individual
wells of the array together with the redundancy provided by the
well-to-well comparison of replicate melt curves results in
exceptionally sensitive and specific organism detection.
We have observed that melting curve analysis is more sensitive
than amplification curves analysis for the detection of input
material. The amount of data collected during the gradual
temperature ramp of the amplicon melt greatly exceeds that
collected during the relatively dynamic temperature cycling of the
second stage PCR. The resulting melt curves have a higher signal
to noise ratio than that of the amplification curves. For several
reasons (e.g. loss of resolution at the high end of dynamic range,
lack of a standard curve on a single sample instrument) the
FilmArray Cq is not a meaningful measure of organism load in the
sample. For this reason, amplification curve data are not reported
in the commercial version of the instrument.
Clinical utility of the FilmArray system
The initial testing of the FilmArray RP pouch with clinical
samples demonstrates a successful real-world application of this
technology. When compared to DFA using pediatric NPA
samples, the platform showed high percent agreement. The most
common reason for discordance was the detection of pathogens by
FilmArray in DFA-negative samples. We believe this is due to the
increased sensitivity of PCR when compared to DFA. In addition,
the ability to test for a much larger panel of pathogens led to a
decrease in the number of negative samples when compared to
conventional testing, and increased the number of instances in
which more than one pathogen was detected in a sample. Other
multiplex PCR-based studies have reported similar findings [86].
The FilmArray instrument and a subset of the assays in the RP
pouch have recently been cleared by the FDA for IVD use and an
initial comparison of the FilmArray instrument with the xTAG
RVP (Luminex Corporation, Austin TX) and conventional
detection methods have been reported [87]. The clinical studies
performed to support the FilmArray application to the FDA used
NPS as the sample matrix. Because the data presented here were
generated on a development version of the instrument and pouch
we do not know the true clinical sensitivity and specificity of the
FilmArray system when using NPA samples.
The advent of diagnostic platforms with the capability of
medium level multiplexing [38,39,88,89,90,91] opens up the
potential for development of a set of multi-pathogen panels that
Table 4. Performance of the FilmArray RP system automated analysis as compared to expert interpretation.
Expert Interpretation RP system Assay Call Percent agreement (95% CI)
Positive Negative
Training Set Positive 12,596 34 99.73 Pos (99.62–99.81)
Negative 4 35,912 99.99 Neg (99.97–100.00)
Validation Set Positive 2,713 8 99.71 Pos (99.42–99.87)
Negative 1 13,119 99.99 Neg (99.96–100.00)
doi:10.1371/journal.pone.0026047.t004
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organism. FilmArray assay panels under development will target
organisms associated with sepsis, meningitis, diarrhea, sexually
transmitted infections, or bioterrorism, as well as genes conferring
antibiotic resistance.
Supporting Information
Table S1 Source of Virus and Bacteria used in this
study.
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